JP2009515994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515994A5 JP2009515994A5 JP2008541372A JP2008541372A JP2009515994A5 JP 2009515994 A5 JP2009515994 A5 JP 2009515994A5 JP 2008541372 A JP2008541372 A JP 2008541372A JP 2008541372 A JP2008541372 A JP 2008541372A JP 2009515994 A5 JP2009515994 A5 JP 2009515994A5
- Authority
- JP
- Japan
- Prior art keywords
- ratio
- use according
- random copolymer
- composition
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 34
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 34
- 229920005604 random copolymer Polymers 0.000 claims 28
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 17
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 17
- 235000019766 L-Lysine Nutrition 0.000 claims 17
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 17
- 239000004472 Lysine Substances 0.000 claims 17
- 229960003767 alanine Drugs 0.000 claims 17
- 229960003646 lysine Drugs 0.000 claims 17
- 229960004441 tyrosine Drugs 0.000 claims 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 16
- 125000000539 amino acid group Chemical group 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 13
- 238000006243 chemical reaction Methods 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 11
- 239000007790 solid phase Substances 0.000 claims 11
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 9
- 229960002989 glutamic acid Drugs 0.000 claims 8
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 229920001577 copolymer Polymers 0.000 claims 6
- 230000002519 immonomodulatory effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108010074605 gamma-Globulins Proteins 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000037884 allergic airway inflammation Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/283,405 | 2005-11-17 | ||
| US11/283,405 US20060194725A1 (en) | 2004-05-07 | 2005-11-17 | Methods of treating disease with random copolymers |
| PCT/US2006/044699 WO2007078443A2 (en) | 2005-11-17 | 2006-11-17 | Methods of treating unwanted immune response with random copolymers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515994A JP2009515994A (ja) | 2009-04-16 |
| JP2009515994A5 true JP2009515994A5 (enExample) | 2009-10-22 |
| JP5676079B2 JP5676079B2 (ja) | 2015-02-25 |
Family
ID=38016876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541372A Expired - Fee Related JP5676079B2 (ja) | 2005-11-17 | 2006-11-17 | ランダムコポリマーによる不要な免疫応答の処置方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060194725A1 (enExample) |
| EP (1) | EP1962880A2 (enExample) |
| JP (1) | JP5676079B2 (enExample) |
| AU (1) | AU2006333437B2 (enExample) |
| CA (1) | CA2630364A1 (enExample) |
| WO (1) | WO2007078443A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20090275496A1 (en) * | 2004-05-07 | 2009-11-05 | Peptimmune, Inc. | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods |
| US7589063B2 (en) * | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
| WO2007047539A2 (en) * | 2005-10-14 | 2007-04-26 | Medtronic, Inc. | Localized delivery to the lymphatic system |
| US20080131441A1 (en) * | 2006-09-26 | 2008-06-05 | Manikkam Suthanthiran | Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection |
| EP2207566A1 (en) | 2007-10-16 | 2010-07-21 | Peptimmune, Inc. | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| SI2949335T1 (sl) | 2009-08-20 | 2017-05-31 | Yeda Research & Development Company, Ltd. | Nizkofrekventna terapija z glatiramer acetatom |
| EA022399B1 (ru) * | 2009-11-17 | 2015-12-30 | Арес Трейдинг С.А. | Способы улучшения дизайна, биодоступности и эффективности композиций полимеров со случайной последовательностью путем основанной на сыворотке детекции композиций полимеров со случайной последовательностью |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| CA3133545C (en) * | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| AU2017290907A1 (en) * | 2016-07-01 | 2019-02-14 | Declion Holdings Llc | Amino acid copolymer compositions and uses thereof |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HRP20250396T1 (hr) | 2016-08-31 | 2025-05-23 | Mapi Pharma Ltd. | Depo sustavi koji sadrže glatiramer acetat |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| AU2020260157A1 (en) | 2019-04-17 | 2021-12-23 | Tempus Ai, Inc. | Collaborative artificial intelligence method and system |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4243834A4 (en) | 2020-11-10 | 2025-05-14 | Palena Therapeutics, Inc. | Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| DK1248643T3 (da) * | 2000-01-20 | 2005-11-07 | Yeda Res & Dev | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi |
| EP1188433B1 (en) * | 2000-09-14 | 2007-01-03 | Firmenich Sa | Use of unsaturated esters as perfuming ingredients |
| HUP0401863A3 (en) * | 2001-10-03 | 2012-09-28 | Harvard College | Amino acid-copolymers for suppression of autoimmune diseases, and methods of use |
| US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| KR20070036062A (ko) * | 2004-05-07 | 2007-04-02 | 펩팀문, 인코포레이티드 | 랜덤 공중합체에 의해 질병을 치료하는 방법 |
-
2005
- 2005-11-17 US US11/283,405 patent/US20060194725A1/en not_active Abandoned
-
2006
- 2006-11-17 AU AU2006333437A patent/AU2006333437B2/en not_active Ceased
- 2006-11-17 CA CA002630364A patent/CA2630364A1/en not_active Abandoned
- 2006-11-17 EP EP06837923A patent/EP1962880A2/en not_active Ceased
- 2006-11-17 JP JP2008541372A patent/JP5676079B2/ja not_active Expired - Fee Related
- 2006-11-17 WO PCT/US2006/044699 patent/WO2007078443A2/en not_active Ceased
-
2014
- 2014-01-31 US US14/169,672 patent/US20140249089A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515994A5 (enExample) | ||
| TWI361696B (en) | A pharmaceutical composition comprising a human anti-tnf帢 antibody or antigen-binding portion thereof and use of a human anti- tnf帢 antibody or antigen-binding portion thereof | |
| JP2014114288A5 (enExample) | ||
| CA2947947C (en) | New indications for anti-il-1-beta therapy | |
| JP2006523682A5 (enExample) | ||
| US7892563B2 (en) | Methods for treatment of severe acute respiratory syndrome (SARS) | |
| TWI823834B (zh) | 包含亞顆粒或核酸支架之顆粒 | |
| Loleit et al. | Current and future therapies targeting the immune system in multiple sclerosis | |
| KR20150040338A (ko) | 다발경화증 치료용 조합 요법 | |
| JP2021028338A (ja) | テノホビルアラフェナミドの結晶形態 | |
| JP2019509257A5 (enExample) | ||
| JP2009521398A5 (enExample) | ||
| CN103172739A (zh) | Il-12/p40结合蛋白 | |
| JP2008540447A5 (enExample) | ||
| JP2007512243A5 (enExample) | ||
| JP2005538034A5 (enExample) | ||
| JP2006519228A5 (ja) | 抗原に対し霊長類を免疫寛容化する抗体の使用法 | |
| Gerner et al. | Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials | |
| JP2006511620A5 (enExample) | ||
| JP2020523384A5 (enExample) | ||
| JP2006508039A5 (enExample) | ||
| CN115279404A (zh) | 人抗tslp抗体的配制品及治疗炎性疾病的方法 | |
| RU2006143334A (ru) | Способы лечения заболеваний с помощью статистических сополимеров | |
| Gill 3rd et al. | The immunogenicity of vinyl polymers. | |
| Craddock et al. | Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing |